![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Sanofi and GSK Land $2.1 Billion Operation Warp Speed Contract
Sanofi and GSK Land $2.1 Billion Operation Warp Speed Contract
![signature.gif](https://www.fdanews.com/ext/resources/test/Device_Images2/signature.gif?t=1596243440&width=430)
August 3, 2020
HHS and the Department of Defense have signed a $2.1 billion contract with Sanofi and GlaxoSmithKline under Operation Warp Speed for the development and manufacturing of their COVID-19 vaccine.
The funding will go toward late-stage development of the vaccine, including a phase 3 clinical trial. The companies will also supply 100 million doses of the vaccine to the federal government.
Sanofi, which is leading the clinical development, plans to begin a phase 1/2 trial of the vaccine candidate next month.
Upcoming Events
-
21Oct